Foundayo® (orforglipron), a New GLP-1 Pill for Weight Loss, Explained

For years, the most effective GLP-1 treatments for obesity have come in the form of weekly injections. Foundayo® (orforglipron) changes that. 

Developed by Eli Lilly, Foundayo® is the newest FDA-approved oral GLP-1 option on the market, and it's designed to make medically supported weight loss more accessible for people who want results without a needle. Here's what you need to know.

What is Foundayo®?

Foundayo® is the brand name for orforglipron, a once-daily prescription weight loss pill made by Eli Lilly. The FDA approved it on April 1, 2026, for adults with obesity or adults who are overweight and have at least one weight-related health condition — such as high blood pressure, high cholesterol, or type 2 diabetes.

It belongs to a class of medications called GLP-1 receptor agonists, the same class as well-known injectable treatments like Wegovy® and Zepbound®. But Foundayo® works differently at a structural level. Unlike those drugs, which are peptide-based and require injection, Foundayo® is a small molecule — meaning it's chemically synthesized, stable in pill form, and can be absorbed orally without any special timing requirements. You can take it any time of day, with or without food.

The only other oral GLP-1 currently available — the Wegovy® pill — has to be taken first thing in the morning on an empty stomach, with a waiting period before you eat or drink anything. Foundayo® has no such restrictions, which makes it a more flexible option for people with busy or unpredictable schedules.

Get prescription weight loss medication — no injection required.

Find out if you're eligible for Foundayo®, and get started on your weight loss journey. Program starting at $75/month .

Get Started Get Started

How Does Foundayo® Work?

Foudayo® mimics GLP-1, a hormone your body naturally produces after you eat. GLP-1 signals to your brain that you're full, slows down how quickly your stomach empties, and helps regulate blood sugar. In people with obesity, this system is often dysregulated, making it harder to feel satisfied after meals and easier to overeat.

By activating GLP-1 receptors in the brain regions that control appetite and caloric intake, Foundayo® helps reduce hunger and makes it easier to eat less without feeling deprived. Over time, that reduction in caloric intake leads to meaningful, sustained weight loss — especially when paired with a reduced-calorie diet and increased physical activity.

What makes Foundayo® distinct is its classification as a small molecule GLP-1 receptor agonist. Most GLP-1 drugs are peptides — large, complex molecules that break down in the digestive tract, which is why they have to be injected. Foundayo® is chemically different: it's small and stable enough to survive the digestive process and be absorbed as a pill. 

Dosing is gradual by design. Treatment starts at 0.8 mg once daily, then increases in steps — to 2.5 mg, then 5.5 mg — with at least 30 days at each level before moving up. The dose can continue to increase up to a maximum of 17.2 mg based on how well you're responding and how well you're tolerating the medication. This slow titration is standard for GLP-1 medications and helps minimize side effects, particularly the GI symptoms that are most common early in treatment.

The Research Behind Foundayo®, Explained

Foundayo®'s FDA approval was supported by the ATTAIN clinical trial program, a large-scale Phase 3 study that evaluated its safety and efficacy in adults with obesity or overweight across two global trials.

In ATTAIN-1, the larger of the two trials, over 3,100 participants were randomized to receive various doses of Foundayo or a placebo alongside a reduced-calorie diet and increased physical activity. After 72 weeks, the results were significant. 

Weight loss was only part of the picture. Across all doses, Foundayo® also produced meaningful improvements in several markers of cardiovascular health, including reductions in waist circumference, triglycerides, non-HDL cholesterol, and systolic blood pressure. For people with obesity who are also managing heart health risks, those secondary benefits matter.

ATTAIN-2 focused specifically on adults with obesity or overweight who also had type 2 diabetes. All three doses of Foundayo® met the trial's primary and key secondary endpoints at 72 weeks, delivering significant weight loss alongside meaningful reductions in A1C — a key measure of long-term blood sugar control.

It's worth noting that in all of these trials, Foundayo® was used in combination with lifestyle changes. The clinical results reflect what's possible when medication is paired with a reduced-calorie diet and increased physical activity, which is also how it's indicated for use in real-world treatment.

How Does Foundayo Compare to Other GLP-1 Options?

Wegovy® and Zepbound® are two of the injectable GLP-1 medications that have dominated the weight loss space over the past few years. Foundayo® works through the same general pathway, but it's not a direct replacement for those drugs. It's a different option, and whether it's the right one depends on your health history, your preferences, and what your doctor recommends.

Here's a general sense of how they differ.

Foundayo® vs. injectable GLP-1s (Zepbound®, Wegovy®)

The injectable GLP-1 medications are currently the most potent options available for weight loss. Clinical trials for those drugs have shown higher average weight loss percentages than Foundayo® at its highest dose. That said, injections aren't the right fit for everyone. 

Some people have needle anxiety, others struggle with the weekly administration routine, and cost and access can be barriers depending on insurance coverage. Foundayo® offers a meaningful alternative for people who want the benefits of a GLP-1 without the injection — at a lower price point and with more flexibility in how and when they take it.

Foundayo® vs. Wegovy® pill

The other oral GLP-1 currently on the market is the Wegovy® pill, which was FDA-approved in December 2025. Both are once-daily pills, but the Wegovy pill must be taken first thing in the morning on an empty stomach, with a 30 minute waiting period before eating or drinking anything. Foundayo can be taken any time of day, with or without food. For people with busy mornings or unpredictable schedules, that flexibility can make a real difference in staying consistent with treatment.

As with any prescription medication, the best way to figure out which option is right for you is to talk to a licensed provider who can look at your full health picture.

Side Effects and Safety Considerations

Like all GLP-1 medications, Foundayo® users may experience side effects. Most of the common side effects are gastrointestinal, tend to be mild to moderate, and typically improve as your body adjusts to the medication — particularly during the early titration phase when doses are still low.

The most commonly reported side effects include nausea, constipation, diarrhea, vomiting, indigestion, and stomach pain. Some people also experience headache, fatigue, bloating, burping, acid reflux, gas, and hair loss. These are consistent with what's been observed across the GLP-1 class broadly, and the gradual dose escalation built into Foundayo®'s dosing schedule is specifically designed to help minimize them.

There are also more serious risks to be aware of. Foundayo® carries a boxed warning — the FDA's most prominent safety label — for the potential risk of thyroid C-cell tumors, including thyroid cancer. Because of this, Foundayo® should not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This warning is standard across the GLP-1 class and has not been observed in human clinical trials, but it's an important consideration to discuss with your doctor.

Additional warnings include inflammation of the pancreas (pancreatitis), severe gastrointestinal reactions, acute kidney injury, low blood sugar (hypoglycemia), serious allergic reactions, diabetic retinopathy complications in patients with type 2 diabetes, and acute gallbladder disease. There is also a precaution around anesthesia — patients should inform their surgical team they are taking Foundayo®, as it may increase the risk of pulmonary aspiration during general anesthesia or deep sedation.

None of this is meant to be alarming. It's meant to reflect what responsible, informed treatment looks like — and why starting any new medication, including Foundayo®, should always involve a conversation with a licensed healthcare provider who knows your full health history.

How to Access Foundayo®

Foundayo® is available in the U.S. now. Eli Lilly has made it accessible through multiple channels — including LillyDirect, telehealth providers, and retail pharmacies nationwide — so getting started doesn't require an in-person visit. LifeMD has integrated with LillyDirect’s pharmacy to provide patients streamlined access to Founday® and other Eli Lilly obesity treatments at pre-negotiated pricing that's often lower than standard retail rates.

Because it's a prescription medication, you'll need to connect with a licensed healthcare provider before you can get it. A provider will review your health history, current medications, and weight-related conditions to determine whether Foundayo® is an appropriate option for you.

Pricing will vary depending on your insurance situation. For people paying out of pocket, Foundayo is available at $149 to $349 per month depending on dose. For insured patients, the cost may be as low as $25 per month. Eligible Medicare Part D enrollees may pay approximately $50 per month beginning July 1, 2026. Lilly has also indicated that some patients using its refill program may qualify for reduced rates on higher doses.

As with any GLP-1 medication, insurance coverage can be inconsistent — and it's worth checking with your plan and your provider to understand what your options are before you start.

How LifeMD Can Help

Foundayo® is a genuine step forward for people who've been hesitant about GLP-1 treatment — whether because of injections, complicated dosing schedules, or cost. It's convenient, clinically backed, and available now.

But like any medication, it's not right for everyone. The best next step is a conversation with a provider who can look at your full health picture and help you figure out what makes sense for you.

That's what LifeMD is here for. 

The LifeMD Weight Management Program combines access to GLP-1 treatment, clinical oversight, and personalized support from licensed healthcare providers who can walk you through your options and help you find an approach to weight management that fits your life. LifeMD also serves as your insurance concierge — verifying coverage, submitting prior authorizations, and providing cost estimates so you have a clear picture of what treatment will look like.

Make an appointment to see if you qualify.